Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1994 2
1998 2
1999 1
2005 2
2006 1
2007 3
2008 4
2009 2
2010 4
2011 4
2013 2
2014 1
2015 1
2018 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Novel bronchodilators in asthma.
Cazzola M, Segreti A, Matera MG. Cazzola M, et al. Curr Opin Pulm Med. 2010 Jan;16(1):6-12. doi: 10.1097/MCP.0b013e32833303d2. Curr Opin Pulm Med. 2010. PMID: 19816179 Review.
RECENT FINDINGS: A variety of beta2-agonists with long half-lives, also called ultra long-acting beta2-agonists (ultra-LABAs; indacaterol, carmoterol, milveterol, GSK-642444, BI-1744-CL, LAS-100977, and PF-00610355) are currently under development with the hopes of achievi …
RECENT FINDINGS: A variety of beta2-agonists with long half-lives, also called ultra long-acting beta2-agonists (ultra-LABAs; indacaterol, …
β(2) -adrenoceptor agonists: current and future direction.
Cazzola M, Calzetta L, Matera MG. Cazzola M, et al. Br J Pharmacol. 2011 May;163(1):4-17. doi: 10.1111/j.1476-5381.2011.01216.x. Br J Pharmacol. 2011. PMID: 21232045 Free PMC article. Review.
A variety of beta(2) -adrenoceptor agonists with long half-lives, also called ultra long-acting beta(2) -adrenoceptor agonists (ultra-LABAs; indacaterol, olodaterol, vilanterol, carmoterol, LAS100977 and PF-610355) are currently under development with the hopes of achievin …
A variety of beta(2) -adrenoceptor agonists with long half-lives, also called ultra long-acting beta(2) -adrenoceptor agonists (ultra-LABAs; …
Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review.
Ridolo E, Montagni M, Olivieri E, Riario-Sforza GG, Incorvaia C. Ridolo E, et al. Int J Chron Obstruct Pulmon Dis. 2013;8:425-32. doi: 10.2147/COPD.S49179. Epub 2013 Sep 18. Int J Chron Obstruct Pulmon Dis. 2013. PMID: 24082783 Free PMC article. Review.
Other very long-acting beta2-agonists currently in development include vilanterol, olodaterol, and carmoterol, and these have shown good characteristics for clinical use in the studies reported thus far....
Other very long-acting beta2-agonists currently in development include vilanterol, olodaterol, and carmoterol, and these have shown g …
Current and novel bronchodilators in respiratory disease.
Spina D. Spina D. Curr Opin Pulm Med. 2014 Jan;20(1):73-86. doi: 10.1097/MCP.0000000000000012. Curr Opin Pulm Med. 2014. PMID: 24247039 Review.
SUMMARY: Novel long-acting beta2-agonists (e.g. indacaterol, vilanterol, olodaterol and carmoterol) and muscarinic antagonists (e.g. tiotropium, aclidinium, glycopyrronium and umeclidinium bromide) document sustained bronchodilation and their combination provides additiona …
SUMMARY: Novel long-acting beta2-agonists (e.g. indacaterol, vilanterol, olodaterol and carmoterol) and muscarinic antagonists (e.g. …
Novel long-acting bronchodilators for COPD and asthma.
Cazzola M, Matera MG. Cazzola M, et al. Br J Pharmacol. 2008 Oct;155(3):291-9. doi: 10.1038/bjp.2008.284. Epub 2008 Jul 7. Br J Pharmacol. 2008. PMID: 18604231 Free PMC article. Review.
Once-daily beta2-agonists or ultra long-acting beta2-agonists (LABAs) such as carmoterol, indacaterol, GSK-159797, GSK-597901, GSK-159802, GSK-642444 and GSK-678007 are under development for the treatment of asthma and COPD. ...
Once-daily beta2-agonists or ultra long-acting beta2-agonists (LABAs) such as carmoterol, indacaterol, GSK-159797, GSK-597901, GSK-15 …
The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor.
Warne T, Moukhametzianov R, Baker JG, Nehmé R, Edwards PC, Leslie AG, Schertler GF, Tate CG. Warne T, et al. Nature. 2011 Jan 13;469(7329):241-4. doi: 10.1038/nature09746. Nature. 2011. PMID: 21228877 Free PMC article.
Here we present four crystal structures of the thermostabilized turkey (Meleagris gallopavo) beta(1)-adrenergic receptor (beta(1)AR-m23) bound to the full agonists carmoterol and isoprenaline and the partial agonists salbutamol and dobutamine. ...
Here we present four crystal structures of the thermostabilized turkey (Meleagris gallopavo) beta(1)-adrenergic receptor (beta(1)AR-m23) bou …
Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.
Tashkin DP, Fabbri LM. Tashkin DP, et al. Respir Res. 2010 Oct 29;11(1):149. doi: 10.1186/1465-9921-11-149. Respir Res. 2010. PMID: 21034447 Free PMC article. Review.
Other LABAs with a 24-hour duration of bronchodilation include carmoterol, vilanterol trifenatate and oldaterol, with early results indicating potential for once-daily dosing in humans.The introduction of once-daily LABAs also provides the opportunity to develop combinatio …
Other LABAs with a 24-hour duration of bronchodilation include carmoterol, vilanterol trifenatate and oldaterol, with early results i …
Long-acting beta-agonists and their association with inhaled corticosteroids in COPD.
Fuso L, Mores N, Valente S, Malerba M, Montuschi P. Fuso L, et al. Curr Med Chem. 2013;20(12):1477-95. doi: 10.2174/0929867311320120003. Curr Med Chem. 2013. PMID: 23409722 Review.
Newer ultra-LABAs, including olodaterol, vilanterol, milveterol, carmoterol, and abediterol, are in development. Combination with ICS (fluticasone/salmeterol, budesonide/formoterol, beclomethasone/formoterol) appears to provide an additional benefit over the monocomponent …
Newer ultra-LABAs, including olodaterol, vilanterol, milveterol, carmoterol, and abediterol, are in development. Combination with ICS …
ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?
Matera MG, Cazzola M. Matera MG, et al. Drugs. 2007;67(4):503-15. doi: 10.2165/00003495-200767040-00002. Drugs. 2007. PMID: 17352511 Review.
This paper reviews the effects of different ultra-LABAs that are at varying stages of development. Arformoterol, carmoterol, indacaterol and GSK-159797 are ultra-LABAs that are likely to be introduced into the market before 2010. ...
This paper reviews the effects of different ultra-LABAs that are at varying stages of development. Arformoterol, carmoterol, indacate …
Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
Ohar JA, Donohue JF. Ohar JA, et al. Semin Respir Crit Care Med. 2010 Jun;31(3):321-33. doi: 10.1055/s-0030-1254072. Epub 2010 May 21. Semin Respir Crit Care Med. 2010. PMID: 20496301 Review.
Novel bronchodilators for COPD in late-stage development include the beta-agonists indacterol and carmoterol. Parasympathetic activity in the large and medium-size airways is mediated through the muscarinic receptors and results in airway smooth-muscle contraction, mucus s …
Novel bronchodilators for COPD in late-stage development include the beta-agonists indacterol and carmoterol. Parasympathetic activit …
30 results